Abstracts tagged "methotrexate (MTX)"

Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
Abstract Number: 2364 • 2019 ACR/ARP Annual Meeting
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
Yoshihiko Hoshida¹, Shiro Ohshima ², Yukihiko Saeki ³, Masao Katayama ⁴, Tomoya Miyamura ⁵, Atsuahi Hashimoto ⁶, Shinji Higa ⁷, Hisaji Oshima ⁸, Masato Yagita ⁹, Yasushi Hiramatsu ¹⁰, Norie Yoshikawa ¹¹, Akiko Mitsuo ¹², Akira Okamoto ¹³, Noriyuki Chiba ¹⁴, Takao Sugiyama ¹⁵, Shouhei Nagaoka ¹⁶, Shoji Sugii ¹⁷, Keigo Setoguchi ¹⁸, Asami Abe ¹⁹, Toshiaki Sugaya ²⁰, Masahiro Koseto ²¹, Yasuo Kunugiza ²², Ryousuke Yoshihara ²³, Shinichiro Tsunoda ²⁴, Tomoaki Fujisaki ²⁵, Hiroshi Furukawa ²⁶, Kazuyoshi Saito ²⁷, Kiyoshi Matsui ²⁸, Yasuhiko Tomita ²⁹ and Shigeto Tohma ³⁰, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, ²NHO Osaka Minami Medical Canter, Kawachinagano, Osaka, Japan, ³NHO Osaka Minami Medical Center, Kawachinagano, Osaka, Japan, ⁴National Hospital Organization Nagoya Medical Center, Nagoya, Japan, ⁵NHO Kyusyu Medical Center, Fukuoka, Japan, ⁶NHO Sagamihara Hospital, Sagamihara, Japan, ⁷Osaka Second Police Hospital, Osaka, Japan, ⁸NHO Tokyo Medical Hospital, Tokyo, Japan, ⁹Kitano Hospital, Osaka, Japan, ¹⁰Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, ¹¹NHO Miyakonojo Medical Center, Miyakonojo, Miyazaki, Japan, ¹²NHO Disaster Medical Center, Tokyo, Tokyo, Japan, ¹³National Hospital Organization HImeji Medical Center, Himeji, Hyogo, Japan, ¹⁴National Hospital Organization Morioka Medical Center, Morioka, Iwate, Japan, ¹⁵NHO Shimoshizu Hospital, Chiba, Chiba, Japan, ¹⁶Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, ¹⁷Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, ¹⁸Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, ¹⁹Niigata Rheumatic Center, Shibata, Niigata, Japan, ²⁰Fuchu Hospital, Izumi, Osaka, Japan, ²¹Nippon Life Hospital, Osaka, Osaka, Japan, ²²JCHO Hoshigaoka Medical Center, Katano, Osaka, Japan, ²³Hyogo Prefecture Kakogawa Hospital, Kakogawa, Hyogo, Japan, ²⁴Sumitomo Hospital, osaka, Osaka, Japan, ²⁵Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan, ²⁶Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ²⁷University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²⁹International University of health and welfare, Narita, Chiba, Japan, ³⁰National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) remains as a major problem to resolve among the patients with rheumatoid arthritis (RA). During few decades, rheumatic therapy has dramatically…
Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
John A. Albert¹, Tony Hosey ² and Brian LaMoreaux ², ¹Rheumatic Disease Center, Milwaukee, IL, ²Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…
Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Jesus Tornero¹, Mercedes Alperi-López ², Ivan Castellvi ³, Juan José de Agustín de Oro ⁴, Alejandro Escudero ⁵, Rosario Garcia-Vicuña ⁶, Miguel Angel González-Gay ⁷, Cristina Hidalgo ⁸, Esteban Rubio ⁹, Raimon Sanmarti ¹⁰, Núria Casamira ¹¹ and Jaime Calvo-Alen ¹², ¹Hospital de Guadalajara, Guadalajara, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Medical Department, Gebro Pharma S.A., Barcelona, Spain, ¹²Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Alain Sánchez-Rodríguez¹, Citlallyc Josefina Gómez-Ruiz ², Abril Montes-Yanes ² and Gabriel Medrano-Ramírez ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
Abstract Number: 1338 • 2019 ACR/ARP Annual Meeting
Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Mojca Frank-Bertoncelj¹, Oliver Distler ², Tim Killeen ³, Kenneth Kwok ⁴, Lisy Wang ⁵, Caroline Ospelt ¹ and Adrian Ciurea ¹, ¹University Hospital Zürich, Zürich, Switzerland, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Pfizer AG, Zürich, Switzerland, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Despite systemic inflammatory cues, RA affects synovial joints variably. Tofacitinib is an oral JAK inhibitor for the treatment of RA. Previous post hoc analyses…
Abstract Number: 2401 • 2019 ACR/ARP Annual Meeting
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
Thierry Dervieux¹, Joel Kremer ², Kelley Brady ¹, Chihiro Takahashi ³, Tsutomu Takeuchi ⁴ and Yuko Kaneko ⁵, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Keio University Hospital Division of Rheumatology, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Methotrexate (MTX) is an anti-folate prodrug activated to MTX polyglutamates (MTXPGs). Japanese Rheumatoid Arthritis (RA) patients are thought to have heightened sensitivity to MTX…
Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Naonori Tsuda¹, Shigeko Inokuma ², Kenichi Hiraga ³, Yoshinori Masui ³ and Toshikazu Kano ³, ¹Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, ²Chiba Central Medical Center, Ichikawa, Chiba, Japan, ³Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan
Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Iván de Jesús Hernández-Galarza ¹, Rita Pineda-Sic¹, Marielva Castro-Gonzalez ¹, Diana Elsa Flores-Alvarado ¹, Octavio Ilizaliturri-Guerra ¹, Rodolfo Uriarte-Botello ¹ and Dionicio Galarza-Delgado ¹, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting
Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Katie Bechman¹, Anuoluwapo Oke ², Mark Yates ³, Sam Norton ³, Elaine Denderson ⁴, Andrew Cope ⁵ and James Galloway ², ¹Kings College London, London, England, United Kingdom, ²Kings College London, London, United Kingdom, ³Kings College London, London, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ⁵Academic Rheumatology, King's College London, London, United Kingdom
Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Renuka Nayak¹, Margaret Alexander ¹, Kye Stapleton-Grey ², Carles Ubeda ³, Jose Scher ⁴ and Peter Turnbaugh ¹, ¹UCSF, San Francisco, ²Carnegie Mellon, Pittsburg, ³Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, ⁴Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…

1
2
3
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].